Pregnancy After Multiple Miscarriages- A Risk-Focused Care Guide

Two or more pregnancy losses before 20 weeks — what clinicians define as recurrent pregnancy loss (RPL) — is one of the most emotionally difficult experiences a couple can go through. It is also one of the most common complications in reproductive medicine: affecting approximately 1–2% of couples trying to conceive, RPL is far from rare. Yet the standard reassurance offered to couples after a first or even second miscarriage — "most are chromosomal flukes, try again" — becomes deeply inadequate after three or more losses, and can delay the investigations that lead to treatable causes and successful pregnancies.

The most important clinical fact about recurrent pregnancy loss is that the majority of couples who receive a thorough investigation and appropriate treatment go on to have a successful pregnancy. This guide explains what causes recurrent miscarriage, what the investigation process involves, and what a risk-focused, specialist-led care approach at Fortis offers in terms of surveillance and support.

⚡ Quick Takeaways

Recurrent pregnancy loss (RPL) is defined as 2 or more pregnancy losses — investigations should begin after 2 losses, not 3, particularly in women over 35.

A treatable cause is found in approximately 50% of couples who undergo thorough investigation — the most common are antiphospholipid syndrome, uterine abnormalities, and thyroid dysfunction.

In the remaining 50%, no cause is found (unexplained RPL) — but even this group has a 60–70% chance of a live birth in a subsequent pregnancy with supportive monitoring care.

Antiphospholipid syndrome (APS) — an autoimmune clotting disorder — is the single most important treatable cause of RPL and is managed with aspirin and heparin during pregnancy.

Specialist surveillance in a subsequent pregnancy after RPL — early viability scans, close hormonal monitoring, and individualised risk management — significantly improves outcomes.

Defining Recurrent Pregnancy Loss: When to Start Investigating

The Royal College of Obstetricians and Gynaecologists (RCOG) and the European Society of Human Reproduction and Embryology (ESHRE) define RPL as the loss of 2 or more pregnancies. This lower threshold — down from the historical definition of 3 losses — reflects evidence that waiting for a third loss before investigating causes unnecessary emotional harm and delays treatment for couples with a correctable underlying condition.

Women over 35 should be investigated after 2 losses without delay. Younger women with 2 losses, particularly where one or both were chromosomally normal (if testing was done), should also be offered investigation rather than empirical "try again" advice. The investigation process is not invasive or complicated — it is primarily a series of blood tests, a uterine assessment, and a review of both partners' history.

Known Causes of Recurrent Pregnancy Loss

Antiphospholipid Syndrome (APS) — The Most Treatable Cause

Antiphospholipid syndrome (APS) is an autoimmune condition in which the immune system produces antibodies against phospholipid-binding proteins, increasing the risk of blood clots in placental blood vessels and impairing embryo implantation and placental development. It is the single most important and treatable cause of RPL, responsible for approximately 15–20% of recurrent miscarriages.

APS is diagnosed by the presence of antiphospholipid antibodies on two occasions at least 12 weeks apart: anticardiolipin antibodies (aCL), anti-beta-2-glycoprotein I antibodies (anti-β2GPI), and lupus anticoagulant (LA). Treatment with low-dose aspirin and low molecular weight heparin (LMWH) during pregnancy significantly improves live birth rates in APS — reducing miscarriage risk by approximately 50% compared to untreated APS.

Uterine Structural Abnormalities

Abnormalities of the uterine cavity that disrupt implantation or placental development account for approximately 10–15% of RPL. These include:

• Uterine septum — a band of fibrous tissue dividing the uterine cavity, the most common congenital uterine anomaly associated with RPL. Hysteroscopic resection of a significant septum significantly improves pregnancy outcomes.
• Submucous fibroids — fibroids projecting into the uterine cavity distort the endometrial lining and can prevent implantation or disrupt early placentation.
• Intrauterine adhesions (Asherman's syndrome) — bands of scar tissue from previous uterine surgery, infection, or D&C procedures, treatable by hysteroscopic adhesiolysis.
• Congenital uterine malformations — bicornuate, arcuate, or unicornuate uterus, which carry varying degrees of RPL risk.
• Assessment of the uterine cavity is best performed by saline infusion sonography (SIS), 3D ultrasound, or hysteroscopy — which provides both diagnosis and treatment opportunity in a single procedure.

Thyroid Dysfunction

Both overt hypothyroidism and subclinical hypothyroidism (elevated TSH with normal T4) are associated with increased miscarriage risk. The thyroid gland plays a critical role in early embryo development and placentation, and even mildly elevated TSH levels (above 2.5 mIU/L in the first trimester by current guidelines) may impair outcomes in RPL patients.

All women with RPL should have thyroid function tested, including TSH and free T4. Thyroid peroxidase antibodies (TPO Ab) should also be checked — thyroid autoimmunity increases miscarriage risk even in women who are currently euthyroid. Levothyroxine supplementation to maintain TSH below 2.5 mIU/L in early pregnancy is recommended for hypothyroid women with RPL.

Chromosomal Abnormalities

Chromosomal testing of products of conception (where available) from pregnancy losses provides the most clinically useful information for understanding the cause of individual losses. Random chromosomal abnormalities (most commonly trisomies) account for 50–60% of individual miscarriages but are less commonly the explanation for recurrent losses — couples with RPL who have had chromosomally abnormal losses predominantly are more likely to have a successful pregnancy on subsequent attempts without specific treatment.

Parental karyotyping — chromosomal analysis of both partners — identifies structural chromosomal rearrangements (most commonly balanced translocations) in approximately 2–5% of RPL couples. Couples with a balanced translocation may benefit from referral for preimplantation genetic testing on embryos through IVF/ICSI.

Hereditary Thrombophilias

Inherited clotting disorders — including Factor V Leiden mutation, prothrombin gene mutation, and protein S, protein C, and antithrombin deficiencies — are associated with some pregnancy complications. Current evidence from RCOG and ESHRE guidelines suggests that thrombophilia testing is appropriate in RPL, though the benefit of heparin treatment in thrombophilia-associated RPL (without APS) is less clearly established than in APS. Testing is still recommended as part of a comprehensive workup.

Endocrine Factors

Uncontrolled diabetes mellitus, polycystic ovary syndrome (PCOS) with associated insulin resistance and elevated LH, and hyperprolactinaemia are all associated with increased miscarriage risk. Blood glucose control before and during pregnancy is essential for women with diabetes. Metformin use in PCOS-associated RPL has been studied, though current evidence is not definitive — discuss with your Fortis specialist.

Unexplained RPL

Despite a comprehensive workup, approximately 50% of RPL couples have no identifiable cause. This is not a reason for despair. Studies from specialist RPL clinics show that couples with unexplained RPL who receive supportive care — including early and frequent scans, psychological support, and regular monitoring — achieve live birth rates of 60–70% in a subsequent pregnancy. The evidence suggests that dedicated specialist attention itself has a therapeutic effect, possibly through optimising implantation support and providing early intervention for complications.

What to Expect From a Fortis RPL Specialist Consultation

A specialist RPL consultation at Fortis involves a comprehensive review of both partners' history, all previous pregnancy details and any available investigation results, and a structured blood and imaging workup. The consultation is the starting point for a care plan for the next pregnancy — not just a list of tests.

For the Woman

Blood tests: antiphospholipid antibodies (×2, 12 weeks apart), full blood count, TSH and free T4, TPO antibodies, random blood glucose, prolactin, karyotype if indicated, Factor V Leiden and prothrombin gene mutation if thrombophilia screening is recommended.

Uterine assessment: 3D pelvic ultrasound; saline infusion sonography or hysteroscopy if ultrasound findings are equivocal or if a submucous fibroid or intrauterine adhesion is suspected.

Products of conception chromosomal analysis: if not done at the time of previous losses and remains possible, this provides the most targeted diagnostic information.

For the Male Partner

• Karyotype: to identify balanced chromosomal translocations.
• Sperm DNA fragmentation testing: high sperm DNA damage is associated with increased early pregnancy loss risk and may influence treatment recommendations.

Management in the Next Pregnancy

Pregnancy management after RPL is not standard antenatal care — it requires a specialist-led surveillance model with more frequent contact, earlier scanning, and proactive management of identified risk factors. A Fortis maternal-fetal medicine (MFM) or reproductive medicine specialist will typically outline:

• Early viability scan at 6–7 weeks to confirm intrauterine location, fetal heartbeat, and dating.
• Follow-up scans at 7–8 weeks and 10–12 weeks for reassurance in the first trimester, when the risk of loss is highest.
• If APS is confirmed: low-dose aspirin started before conception and LMWH (enoxaparin) from a positive pregnancy test, continued through at least 34 weeks.
• If thyroid antibodies are positive or TSH is elevated: levothyroxine titration to maintain TSH below 2.5 mIU/L, with monthly thyroid function monitoring in early pregnancy.
• Psychological support: the anxiety of a pregnancy after RPL is significant and clinically recognised. Discuss counselling or psychological support with your Fortis care team — it is part of the clinical management, not an optional add-on.

When to Refer to a Maternal-Fetal Medicine (MFM) Specialist

Not all RPL care requires MFM involvement, but referral to a Fortis MFM specialist is appropriate when:

• Three or more pregnancy losses have occurred, particularly with a negative or incomplete workup.
• APS is confirmed — combined aspirin and heparin management during pregnancy requires experienced specialist oversight.
• A structural uterine abnormality has been identified — assessment of whether correction is appropriate requires specialist input.
• A balanced translocation has been found in either partner — genetic counselling and discussion of PGT-A options require a specialist familiar with assisted reproduction and genetics.
• The woman is over 38 — advanced maternal age combined with RPL creates a compounded risk profile that benefits from MFM-level assessment.